The Middle East molecular diagnostics market is projected to reach $1,017.7 million by 2031 from $493.1 million in 2020, at a CAGR of 6.72% during the forecast period 2021-2031.

1. All rights reserved at BIS Research Inc. 1
M
I
D
D
L
E
E
A
S
T
M
O
L
E
C
U
L
A
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Focus on Product, Testing Location,
Technology, Application, End User, and
Country Data
Analysis and Forecast: 2021-2031
May 2022
Middle East
Molecular
Diagnostics
Market-
Country Analysis
Table of Content

2. All rights reserved at BIS Research Inc. 2
M
I
D
D
L
E
E
A
S
T
M
O
L
E
C
U
L
A
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
BIS Research is a leading market intelligence and technology research company. BIS Research publishes in-
depth market intelligence reports focusing on the market estimations, technology analysis, emerging high-
growth applications, deeply segmented granular country-level market data and other important market
parameters useful in the strategic decision making for senior management. BIS Research provides multi-client
reports, company profiles, databases, and custom research services.
Copyright © 2022 BIS Research Inc.
All Rights Reserved. This document contains highly confidential information and is the sole property of BIS
Research. Disclosing, copying, circulating, quoting or otherwise reproducing any or all contents of this
document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people
or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third
party.

3. All rights reserved at BIS Research Inc. 3
M
I
D
D
L
E
E
A
S
T
M
O
L
E
C
U
L
A
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Table of Content
Executive Summary ........................................................................ 17
Research Methodology ................................................................... 23
Scope of the Study.......................................................................... 28
1 Middle East Molecular Diagnostics Market ................................ 30
1.1 Product Definition............................................................................................30
1.1.1 Inclusion and Exclusion .............................................................................30
1.2 Market Overview ..............................................................................................31
1.3 Historical Perspective .....................................................................................32
1.4 Significant Technologies ................................................................................33
1.5 Classification of Molecular Diagnostics ........................................................34
1.6 Future Potential ...............................................................................................36
2 Industry Insights....................................................................... 37
2.1 Patent Analysis................................................................................................38
2.1.1 Patent Filing Trend......................................................................................38
2.2 Legal Requirements ........................................................................................38
2.2.1 Legal Requirements and Framework in the U.S. ......................................38
2.2.2 U.S. FDA Regulations..................................................................................39
3 Competitive Landscape ............................................................ 40
3.1 Competitive Landscape ..................................................................................41
3.1.1 Acquisitions.................................................................................................41
3.1.2 Synergistic Activities ..................................................................................42
3.1.3 Product Launches and Upgradations........................................................43
3.1.4 Business Expansion ...................................................................................44
4 Market Dynamics...................................................................... 45
4.1 Market Dynamics .............................................................................................46
4.1.1 Impact Analysis ...........................................................................................46
4.1.2 Market Drivers .............................................................................................47

4. All rights reserved at BIS Research Inc. 4
M
I
D
D
L
E
E
A
S
T
M
O
L
E
C
U
L
A
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
4.1.2.1 Increasing Prevalence of Infectious Diseases and Various Types of Cancer
in the Middle East.............................................................................................47
4.1.2.2 Increase in Awareness and Acceptance of Personalized Medicines in the
Middle East ......................................................................................................49
4.1.2.3 Significant External Funding for Executing Research and Development
Exercises .........................................................................................................49
4.1.3 Market Restraints ........................................................................................50
4.1.3.1 Uncertain Reimbursement Scenario.................................................................50
4.1.3.2 Lack of High-Complexity Testing Centers in the Middle East............................50
4.1.4 Market Opportunities ..................................................................................51
4.1.4.1 Massive Scope for Adoption of Molecular Diagnostics .....................................51
4.1.4.2 Rise of Next-Generation Ultrasensitive Molecular Diagnostics .........................51
4.1.4.3 Novel Revenue Streams ..................................................................................52
4.2 COVID-19 Impact on Middle East Molecular Diagnostics Market ................53
4.2.1 Impact on Market Size.................................................................................54
4.2.2 Impact on Molecular Diagnostic Practices................................................54
5 Middle East Molecular Diagnostics Market, by Products,
$Million, 2021 - 2031................................................................. 55
5.1 Overview...........................................................................................................56
5.1.1 Systems........................................................................................................57
5.1.2 Kits and Consumables................................................................................58
5.1.3 Software and Other Products.....................................................................61
6 Middle East Molecular Diagnostics Market, by Testing
Location, $Million, 2021 - 2031.................................................. 64
6.1 Overview...........................................................................................................65
6.1.1 Laboratory Testing......................................................................................66
6.1.2 Point-of-Care Testing..................................................................................67
7 Middle East Molecular Diagnostics Market, by Technology,
$Million, 2021 - 2031................................................................. 69
7.1 Overview...........................................................................................................70
7.1.1 Polymerase Chain Reaction (PCR) ............................................................71

5. All rights reserved at BIS Research Inc. 5
M
I
D
D
L
E
E
A
S
T
M
O
L
E
C
U
L
A
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
7.1.2 Next-Generation Sequencing .....................................................................74
7.1.3 Isothermal Nucleic Acid Amplification Technology (INAAT)...................75
7.1.4 Microarray....................................................................................................77
7.1.5 In-Situ Hybridization (ISH) ..........................................................................79
7.1.6 Immunohistochemistry (IHC) .....................................................................80
7.1.7 Other Technologies.....................................................................................82
8 Middle East Molecular Diagnostics Market, by Application,
$Million, 2021 - 2031................................................................. 84
8.1 Overview...........................................................................................................85
8.1.1 Core Molecular Diagnostics .......................................................................86
8.1.2 Reproductive Genetics ...............................................................................87
8.1.3 Companion Diagnostics (CDx)...................................................................88
8.1.4 Liquid Biopsy...............................................................................................89
8.1.5 Other Applications ......................................................................................90
9 Middle East Molecular Diagnostics Market, by End User,
$Million, 2021 - 2031................................................................. 92
9.1 Overview...........................................................................................................93
9.1.1 Hospitals ......................................................................................................94
9.1.2 Diagnostic Centers......................................................................................95
9.1.3 Out-Patient Clinics/General Practitioners .................................................96
9.1.4 Research Laboratories................................................................................97
9.1.5 Other End Users ..........................................................................................98
10 Middle East molecular diagnostics Market, by Country,
$Million, 2020-2031................................................................... 99
10.1 Overview.........................................................................................................100
10.1.1 Kingdom of Saudi Arabia (KSA)...............................................................101
10.1.2 Israel...........................................................................................................103
10.1.3 United Arab Emirates (U.A.E.) ..................................................................104
10.1.4 Egypt ..........................................................................................................105
10.1.5 Iran..............................................................................................................106
10.1.6 Qatar...........................................................................................................107

6. All rights reserved at BIS Research Inc. 6
M
I
D
D
L
E
E
A
S
T
M
O
L
E
C
U
L
A
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
10.1.7 Rest-of-the-Middle East ............................................................................108
11 Market - Competitive Benchmarking & Company Profiles ........ 109
11.1 Overview.........................................................................................................110
11.2 Abbott. ............................................................................................................111
11.2.1 Company Overview ...................................................................................111
11.2.2 Role of Abbott. in the Middle East Molecular Diagnostics Market........111
11.2.3 Key Competitors of the Company............................................................111
11.2.4 Key Customers of the Company ..............................................................111
11.2.5 Business Strategies ..................................................................................112
11.2.6 Financials...................................................................................................113
11.2.7 Key Insights about Financial Health of the Company............................115
11.2.8 SWOT Analysis..........................................................................................116
11.3 Agilent Technologies, Inc. ............................................................................117
11.3.1 Company Overview ...................................................................................117
11.3.2 Role of Agilent Technologies, Inc. in the Middle East Molecular
Diagnostics Market....................................................................................117
11.3.3 Key Competitors of the Company............................................................117
11.3.4 Key Customers of the Company ..............................................................117
11.3.5 Business Strategies ..................................................................................118
11.3.6 Corporate Strategies:................................................................................118
11.3.7 Financials...................................................................................................119
11.3.8 Key Insights about Financial of the Company........................................121
11.3.9 SWOT Analysis..........................................................................................122
11.4 bioMérieux SA................................................................................................123
11.4.1 Company Overview ...................................................................................123
11.4.2 Role of bioMérieux SA in the Middle East Molecular Diagnostics
Market.........................................................................................................123
11.4.3 Key Competitors of the Company............................................................123
11.4.4 Key Customers of the Company ..............................................................123
11.4.5 Business Strategies ..................................................................................124

7. All rights reserved at BIS Research Inc. 7
M
I
D
D
L
E
E
A
S
T
M
O
L
E
C
U
L
A
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
11.4.6 Financials...................................................................................................125
11.4.7 Key Insights about the Financial Health of the Company......................126
11.4.8 SWOT Analysis..........................................................................................127
11.5 BD. ..................................................................................................................128
11.5.1 Company Overview ...................................................................................128
11.5.2 Role of BD. in the Middle East Molecular Diagnostics Market ..............128
11.5.3 Key Competitors of the Company............................................................128
11.5.4 Key Customers of the Company ..............................................................129
11.5.5 Business Strategies ..................................................................................129
11.5.6 Financials...................................................................................................130
11.5.7 Key Insights about Financial Health of the Company............................132
11.5.8 SWOT Analysis..........................................................................................133
11.6 Babirus Medical Equipment LLC..................................................................134
11.6.1 Company Overview ...................................................................................134
11.6.2 Role of Babirus Medical Equipment Trading LLC in the Middle East
Molecular Diagnostics Market..................................................................134
11.6.3 Key Competitors of the Company............................................................134
11.6.4 Key Customers of the Company ..............................................................134
11.6.5 Business Strategies ..................................................................................135
11.6.6 SWOT Analysis..........................................................................................136
11.7 Bio-Rad Laboratories, Inc. ............................................................................137
11.7.1 Company Overview ...................................................................................137
11.7.2 Role of Bio-Rad Laboratories, Inc. in the Middle East Molecular
Diagnostics Market....................................................................................137
11.7.3 Key Competitors of the Company............................................................137
11.7.4 Key Customers of the Company ..............................................................138
11.7.5 Business Strategies ..................................................................................138
11.7.5.1 Corporate Strategies ......................................................................................138
11.7.6 Financials...................................................................................................139
11.7.7 Key Insights about Financial Health of the Company............................141

8. All rights reserved at BIS Research Inc. 8
M
I
D
D
L
E
E
A
S
T
M
O
L
E
C
U
L
A
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
11.7.8 SWOT Analysis..........................................................................................142
11.8 Danaher. .........................................................................................................143
11.8.1 Company Overview ...................................................................................143
11.8.2 Role of Danaher. in the Middle East Molecular Diagnostics Market .....143
11.8.3 Key Competitors of the Company............................................................143
11.8.4 Key Customers of the Company ..............................................................143
11.8.5 Business Strategies ..................................................................................144
11.8.6 Corporate Strategies.................................................................................144
11.8.7 Financials...................................................................................................145
11.8.8 Key Insights about Financial Health of the Company............................147
11.8.9 SWOT Analysis..........................................................................................148
11.9 F. Hoffmann-La Roche Ltd............................................................................149
11.9.1 Company Overview ...................................................................................149
11.9.2 Role of F. Hoffmann-La Roche Ltd. in the Middle East Molecular
Diagnostics Market....................................................................................149
11.9.3 Key Competitors of the Company............................................................149
11.9.4 Key Customers of the Company ..............................................................149
11.9.5 Business Strategies ..................................................................................150
11.9.6 Corporate Strategies.................................................................................150
11.9.7 Financials...................................................................................................151
11.9.8 Key Insights about Financial Health of the Company............................153
11.9.9 SWOT Analysis..........................................................................................154
11.10 Guardant Health.............................................................................................155
11.10.1 Company Overview.............................................................................155
11.10.2 Role of Guardant Health in the Middle East Molecular
Diagnostics Market....................................................................................155
11.10.3 Key Competitors of the Company .....................................................155
11.10.4 Key Customers of the Company........................................................156
11.10.5 Corporate Strategies...........................................................................156
11.10.6 Financials ............................................................................................156

9. All rights reserved at BIS Research Inc. 9
M
I
D
D
L
E
E
A
S
T
M
O
L
E
C
U
L
A
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
11.10.7 Key Insights about Financial Health of the Company......................158
1.1.1 SWOT Analysis..........................................................................................159
11.11 Illumina, Inc....................................................................................................160
11.11.1 Company Overview.............................................................................160
11.11.2 Role of Illumina, Inc. in the Middle East Molecular Diagnostics
Market.........................................................................................................160
11.11.3 Key Competitors of the Company .....................................................160
11.11.4 Key Customers of the Company........................................................160
11.11.5 Corporate Strategies...........................................................................161
11.11.6 Financials ............................................................................................162
11.11.7 Key Insights about the Financial Health of the Company ...............163
11.11.8 SWOT Analysis....................................................................................164
11.12 QIAGEN N.V....................................................................................................165
11.12.1 Company Overview.............................................................................165
11.12.2 Role of QIAGEN N.V. in the Middle East Molecular Diagnostics
Market.........................................................................................................165
11.12.3 Key Competitors of the Company .....................................................166
11.12.4 Key Customers of the Company........................................................166
11.12.5 Corporate Strategies...........................................................................166
11.12.6 Key Insights about Financial Health of the Company......................169
11.12.7 SWOT Analysis....................................................................................170
11.13 Thermo Fisher Scientific Inc.........................................................................171
11.13.1 Company Overview.............................................................................171
11.13.2 Role of Thermo Fisher Scientific Inc. in the Middle East
Molecular Diagnostics Market..................................................................171
11.13.3 Key Competitors of the Company .....................................................172
11.13.4 Key Customers of the Company........................................................172
11.13.5 Business Strategies............................................................................172
11.13.6 Financials ............................................................................................173
11.13.7 Key Insights about Financial Health of the Company......................174
11.13.8 SWOT Analysis....................................................................................175

10. All rights reserved at BIS Research Inc. 10
M
I
D
D
L
E
E
A
S
T
M
O
L
E
C
U
L
A
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
List of Figures
Figure 1: Middle East Molecular Diagnostics Market-Market Dynamics
Figure 2: Share of Key Market Strategies and Developments, January 2017-September 2021
Figure 3: Middle East Molecular Diagnostics Market Snapshot, $Million, 2020-2031
Figure 4: Middle East Molecular Diagnostics Market (by Product), $Million, 2020 Vs. 2031
Figure 5: Middle East Molecular Diagnostics Market (by Technology), $Million, 2020 Vs. 2031
Figure 6: Middle East Molecular Diagnostics Market (by Application), $Million, 2020 Vs. 2031
Figure 7: Middle East Molecular Diagnostics Market (by End User), $Million, 2020 Vs. 2031
Figure 8: Middle East Molecular Diagnostics Market Research Methodology
Figure 9: Middle East Molecular Diagnostics Market: Segmentation
Figure 10: Role of Diagnostics in Healthcare
Figure 11: Evolution of Molecular Diagnostics
Figure 12: Classification of Molecular Diagnostics
Figure 13: Year-Wise Analysis of Patents Related to Molecular Diagnostics, January 2019-October 2021
Figure 14: Share of Key Developments and Strategies, January 2017-September 2021
Figure 15: Share of Acquisitions (by Company), January 2017-September 2021
Figure 16: Share of Synergistic Activities (by Company), January 2017-September 2021
Figure 17: Share of Product Launches and Upgradations (by Company), January 2017-September 2021
Figure 18: Share of Business Expansion (by Company), July 2017-August 2021
Figure 19: Middle East Molecular Diagnostics Market - Market Dynamics
Figure 20: Rate of Cancer Incidence and Death in 2020
Figure 21: Personalized Care for Cancer Patients
Figure 22: Impact of COVID-19 on Middle East Molecular Diagnostics Market
Figure 23: Share of Middle East Molecular Diagnostics Market (by Product), $Million, 2020 and 2031
Figure 24: Middle East Molecular Diagnostics Market (Systems), $Million, 2020-2031
Figure 25: General Workflow of a Molecular Diagnostic Kit
Figure 26: Middle East Molecular Diagnostics Market (Kits and Consumables), $Million, 2020-2031
Figure 27: Aspects of Software Development
Figure 28: Middle East Molecular Diagnostics Market (Software and Other Products), $Million, 2020-
2031
Figure 29: Middle East Molecular Diagnostics Market (by Testing Location)

11. All rights reserved at BIS Research Inc. 11
M
I
D
D
L
E
E
A
S
T
M
O
L
E
C
U
L
A
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Figure 30: Share of Middle East Molecular Diagnostics Market (by Testing Location), $Million, 2020 and
2031
Figure 31: Middle East Molecular Diagnostics Market (Laboratory Testing), $Million, 2020-2031
Figure 32: Middle East Molecular Diagnostics Market (Point-of-Care Testing), $Million, 2020-2031
Figure 33: Share of Middle East Molecular Diagnostics Market (by Technology), $Million, 2020 and 2031
Figure 34: Middle East Molecular Diagnostics Market (Polymerase Chain Reaction), $Million, 2020-2031
Figure 35: Middle East Molecular Diagnostics Market (Next-Generation Sequencing), $Million, 2020-
2031
Figure 36: Middle East Molecular Diagnostics Market (Isothermal Nucleic Acid Amplification Technology),
$Million, 2020-2031
Figure 37: Middle East Molecular Diagnostics Market (Microarray), $Million, 2020-2031
Figure 38: Middle East Molecular Diagnostics Market (ISH), $Million, 2020-2031
Figure 39: Middle East Molecular Diagnostics Market (IHC), $Million, 2020-2031
Figure 40: Middle East Molecular Diagnostics Market (Other Technologies), $Million, 2020-2031
Figure 41: Middle East Molecular Diagnostics Market (by Application), $Million, 2020 and 2031
Figure 42: Middle East Molecular Diagnostics Market (Core Molecular Diagnostics), $Million, 2020-2031
Figure 43: Middle East Molecular Diagnostics Market (Reproductive Genetics), $Million, 2020-2031
Figure 44: Middle East Molecular Diagnostics Market (Companion Diagnostics), $Million, 2020-2031
Figure 45: Middle East Molecular Diagnostics Market (Liquid Biopsy), $Million, 2020-2031
Figure 46: Middle East Molecular Diagnostics Market (Other Applications), $Million, 2020-2031
Figure 47: Share of Middle East Molecular Diagnostics Market (by End User), $Million, 2020 and 2031
Figure 48: Middle East Molecular Diagnostics Market (Hospitals), $Million, 2020-2031
Figure 49: Middle East Molecular Diagnostics Market (Diagnostic Centers), $Million, 2020-2031
Figure 50: Middle East Molecular Diagnostics Market (Out-Patient Clinics/General Practitioners),
$Million, 2020-2031
Figure 51: Middle East Molecular Diagnostics Market (Research Laboratories), $Million, 2020-2031
Figure 52: Middle East Molecular Diagnostics Market (Other End Users), $Million, 2020-2031
Figure 53: Middle East Molecular Diagnostics Market (by Country), $Million, 2020-2031
Figure 54: Middle East Molecular Diagnostics Market (by Country), 2021 and 2031
Figure 55: Kingdom of Saudi Arabia Diagnostics Market $Million, 2020-2031
Figure 56: Israel Molecular Diagnostics Market, $Million, 2020-2031
Figure 57: U.A.E. Molecular Diagnostics Market, $Million, 2020-2031
Figure 58: Egypt Molecular Diagnostics Market, $Million, 2020-2031

12. All rights reserved at BIS Research Inc. 12
M
I
D
D
L
E
E
A
S
T
M
O
L
E
C
U
L
A
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Figure 59: Iran Molecular Diagnostics Market, $Million, 2020-2031
Figure 60: Qatar Molecular Diagnostics Market, $Million, 2020-2031
Figure 61: Rest-of-the-Middle East Molecular Diagnostics Market, $Million, 2020-2031
Figure 62: Total Number of Companies Profiled
Figure 63: Abbott.: Overall Product Portfolio
Figure 64: Abbott.: Overall Financials, 2019-2021
Figure 65: Abbott.: Revenue (by Segment), 2019-2021
Figure 66: Abbott.: Revenue (by Region), 2019-2021
Figure 67: Abbott.: R&D Expenditure, 2019-2021
Figure 68: Abbott.: SWOT Analysis
Figure 69: Agilent Technologies, Inc.: Overall Product Portfolio
Figure 70: Agilent Technologies, Inc.: Overall Financials, 2019-2021
Figure 71: Agilent Technologies, Inc.: Revenue (by Segment), 2019-2021
Figure 72: Agilent Technologies, Inc.: Revenue (by Region), 2019-2021
Figure 73: Agilent Technologies, Inc.: R&D Expenditure, 2019-2021
Figure 74: Agilent Technologies, Inc.: SWOT Analysis
Figure 75: bioMérieux SA: Product Portfolio
Figure 76: bioMérieux SA: Overall Financials, $Million, 2019-2021
Figure 77: bioMérieux SA: Revenue (by Segment), $Million, 2019-2021
Figure 78: bioMérieux SA: Revenue (by Region), $Million, 2019-2021
Figure 79: bioMérieux SA: R&D Expenditure, $Million, 2019-2021
Figure 80: bioMérieux SA: SWOT Analysis
Figure 81: BD.: Overall Product Portfolio
Figure 82: BD.: Overall Financials, 2019-2021
Figure 83: BD.: Revenue (by Segment), 2019-2021
Figure 84: BD.: Revenue (by Region), 2019-2021
Figure 85: BD.: R&D Expenditure, 2019-2021
Figure 86: BD.: SWOT Analysis
Figure 87: Babirus Medical Equipment Trading LLC: Overall Product Portfolio
Figure 88: Babirus Medical Equipment Trading LLC: SWOT Analysis
Figure 89: Bio-Rad Laboratories, Inc.: Overall Product Portfolio
Figure 90: Bio-Rad Laboratories, Inc.: Overall Financials, 2019-2021
Figure 91: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2019-2021

13. All rights reserved at BIS Research Inc. 13
M
I
D
D
L
E
E
A
S
T
M
O
L
E
C
U
L
A
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Figure 92: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2019-2021
Figure 93: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2019-2021
Figure 94: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 95: Danaher.: Overall Product Portfolio
Figure 96: Danaher.: Overall Financials, 2019-2021
Figure 97: Danaher.: Revenue (by Segment), 2019-2021
Figure 98: Danaher.: Revenue (by Region), 2019-2021
Figure 99: Danaher.: R&D Expenditure, 2019-2021
Figure 100: Danaher.: SWOT Analysis
Figure 101: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 102: F. Hoffmann-La Roche Ltd: Overall Financials, 2019-2021
Figure 103: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2019-2021
Figure 104: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2019-2021
Figure 105: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2019-2021
Figure 106: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 107: Guardant Health: Overall Product Portfolio
Figure 108: Guardant Health: Overall Financials, 2018-2020
Figure 109: Guardant Health: Revenue (by Segment), 2018-2020
Figure 110: Guardant Health: R&D Expenditure, 2018-2020
Figure 111: Guardant Health: SWOT Analysis
Figure 112: Illumina, Inc.: Product Portfolio
Figure 113: Illumina, Inc.: Overall Financials, $Million, 2019-2021
Figure 114: Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 115: Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 116: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 117: Illumina, Inc.: SWOT Analysis
Figure 118: QIAGEN N.V.: Overall Product Portfolio
Figure 119: QIAGEN N.V.: Overall Financials, 2019-2021
Figure 120: QIAGEN N.V.: Revenue (by Segment), 2019-2021
Figure 121: QIAGEN N.V.: Revenue (by Region), 2019-2021
Figure 122: QIAGEN N.V.: R&D Expenditure, 2019-2021
Figure 123: QIAGEN N.V.: SWOT Analysis
Figure 124: Thermo Fisher Scientific Inc.: Overall Product Portfolio

14. All rights reserved at BIS Research Inc. 14
M
I
D
D
L
E
E
A
S
T
M
O
L
E
C
U
L
A
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Figure 125: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
Figure 126: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), $Million, 2019-2021
Figure 127: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2019-2021
Figure 128: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021
Figure 129: Thermo Fisher Scientific Inc.: SWOT Analysis

15. All rights reserved at BIS Research Inc. 15
M
I
D
D
L
E
E
A
S
T
M
O
L
E
C
U
L
A
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
List of Tables
Table 1: COVID-19 Impact on Middle East Molecular Diagnostics Market

16. All rights reserved at BIS Research Inc. 16
M
I
D
D
L
E
E
A
S
T
M
O
L
E
C
U
L
A
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
BIS Research Offerings:
We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s
digital age. We have a vision to be a leading and a preferred knowledge partner for corporates and institutions
worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other
innovative solutions.
Know More Know More
Know More
Know More

17. All rights reserved at BIS Research Inc. 17
M
I
D
D
L
E
E
A
S
T
M
O
L
E
C
U
L
A
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
Disclaimer
BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to
orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth.
This document and its contents are confidential and may not be further distributed, published or reproduced,
in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS
Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly
through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information
to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce
Information in legal proceedings.
Market reports are based on expectations, estimates and projections as of the date such information is
available. Any recommendation contained in this report may not be suitable for all investors or businesses.
The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while
considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to
market fluctuations and business, economic and competitive uncertainties and contingencies.
For more details regarding permission, please contact us:
Email: sales@bisresearch.com
Tel: +1 510 404 8135

18. All rights reserved at BIS Research Inc. 18
M
I
D
D
L
E
E
A
S
T
M
O
L
E
C
U
L
A
R
D
I
A
G
N
O
S
T
I
C
S
M
A
R
K
E
T
BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544
www.bisresearch.com